Corey J. Langer, MD

Corey J. Langer, MD

Episodes

Specialty:

All

Year:

All

EP. 1: Looking Ahead to the Next Game-Changer in Lung Cancer

October 1st 2015

EP. 2: CAR T-Cell Therapy in Lung Cancer

October 1st 2015

EP. 3: Immunotherapy: Potential for Higher Cure Rates in Lung Cancer

October 1st 2015

EP. 4: Applying Immunotherapy Learnings in Melanoma to Lung Cancer

October 1st 2015

EP. 5: Checkpoint Inhibition Squamous Cell and Nonsquamous Cell NSCLC

October 1st 2015

EP. 6: Activity of Afatinib in Lung Cancer

October 1st 2015

EP. 7: LUX-Lung 8: Afatinib Survival Benefit in Squamous NSCLC

October 1st 2015

EP. 8: Benefits of Liquid Biopsies in Lung Cancer

October 1st 2015

EP. 9: EGFR-Resistant Disease in Lung Cancer

October 1st 2015

EP. 10: Role of Gefitinib in EGRF-Mutant NSCLC

October 1st 2015

EP. 11: Changing Treatment Landscape in Advanced Lung Cancer

October 1st 2015

Trending on OncLive

Five Under 5: Top Oncology Videos for the Week of 8/31/26

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

The OncFive: Top Oncology Articles for the Week of 8/30

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC